Teal Health Launches FDA-Authorized At-Home Cervical Cancer Screening Nationwide

New updates have been reported about Teal Health.

Teal Health has moved into full national commercialization of its at-home cervical cancer screening solution, making its FDA-authorized Teal Wand self-collection device and virtual care platform available to women in all 50 U.S. states. The expansion comes just seven months after Teal secured the first and only FDA authorization for at-home cervical cancer screening in May 2025, and aligns with newly updated guidelines from the American Cancer Society and the U.S. Department of Health and Human Services that explicitly recommend or endorse HPV self-collection and require insurance coverage for screening and follow-up by January 2027. Women can now order a kit directly through Teal’s platform, complete a brief telehealth visit to confirm eligibility, collect an HPV sample at home using the same FDA-approved test used in clinics, and receive results and follow-up via a secure portal, with the option to share records with existing providers to keep care coordinated.

The company’s go-to-market model combines insurance reimbursement, direct payment, and partnerships with payers, health systems, employers, and provider organizations, with pricing set at $99 for in-network insured patients and $249 self-pay, and eligibility for HSA/FSA payment. Teal is targeting the large underscreened population—about one in three U.S. women are behind on cervical cancer screening—arguing that convenience, privacy, and reduced procedural discomfort can drive higher adherence, similar to proven uptake in at-home colorectal cancer screening programs. In a 16-site national clinical trial, Teal Wand self-collected samples matched clinician-collected performance, detecting cervical precancer 96% of the time, and 94% of participants preferred the at-home method; early commercial users have also given high satisfaction scores. With federal policy now favoring self-collection, guideline backing, and demonstrated clinical equivalence, Teal is positioned to capture a meaningful share of the cervical cancer screening market while influencing payer strategy, employer benefits design, and health system outreach programs focused on preventive care and population health metrics.